Results 81 to 90 of about 5,641 (160)

Treatment of Central Serous Chorioretinopathy With Topical Difluprednate: A Literature Review. [PDF]

Cureus
Chatterjee SK, Khuddus N.
europepmc   +1 more source

Long-term clinical outcomes and prognostic factors of central serous chorioretinopathy. [PDF]

BMC Ophthalmol
Na DG, Kim CG, Kim JH.
europepmc   +1 more source

Effects of Selective Retina Therapy on Central Serous Chorioretinopathy with Serous Pigment Epithelial Detachments. [PDF]

J Clin Med
Kim D, Jeon SH, Roh YJ.
europepmc   +1 more source

Clinical and multimodal imaging characteristics of acute central serous chorioretinopathy with fibrinous exudation. [PDF]

Int J Ophthalmol
Liu ZC, Zhang J, Han JD.
europepmc   +1 more source

Steroidome Dysregulation and Complement C4 Copy Number Variation in Men With Central Serous Chorioretinopathy. [PDF]

Invest Ophthalmol Vis Sci
Zola M, Han JH, Quinodoz M, Bousquet E, Matet A, Kowalczuk L, Daruich A, Zhao M, Ullah M, Rivolta C, Eandi C, Arsenijevicz Y, Pussard E, Behar-Cohen F.   +13 more
europepmc   +1 more source

Beyond the vision: central serous chorioretinopathy, anxiety and depression-a systematic review. [PDF]

Front Med (Lausanne)
Meduri A, Merlo EM, Sparacino G, Mancini M, Oliverio GW, Silvestro O, De Luca L, Martino G, Aragona P.   +8 more
europepmc   +1 more source

Ultrawide-field indocyanine angiography changes post 12 weeks of eplerenone in central serous chorioretinopathy. [PDF]

Indian J Ophthalmol
Sagar A, Mishra S, Kumar P, Sati A, Gupta A, Avasthi A, Srujana D, Dhar S, Khaleel M, Joshi A.   +9 more
europepmc   +1 more source

Outcomes of Treatment for Central Serous Chorioretinopathy With Half-Fluence, Half-Dose Photodynamic Therapy. [PDF]

J Vitreoretin Dis
Mishra AV, Deonarain DM, Loh GK, Tennant MTS.   +3 more
europepmc   +1 more source

Choroidal neovascularization as a trigger for central serous chorioretinopathy. [PDF]

Int J Retina Vitreous
Vienne-Jumeau A, Bousquet E, Bijon J, Mrejen S, Behar-Cohen F.   +4 more
europepmc   +1 more source

Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy. [PDF]

Int J Ophthalmol
Joo JY, Jun YH, Kim ST.
europepmc   +1 more source